Peritoneal Neoplasms [clinicaltrials_resource:8436df17cb6a67e09076d0e4df2e0379]
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis [clinicaltrials:NCT00001332]EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer [clinicaltrials:NCT00035100]clinicaltrials:NCT00063401Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer [clinicaltrials:NCT00074867]Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers [clinicaltrials:NCT00086567]Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response [clinicaltrials:NCT00103545]clinicaltrials:NCT00112086clinicaltrials:NCT00183794Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients [clinicaltrials:NCT00189345]A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. [clinicaltrials:NCT00191607]clinicaltrials:NCT00191646Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis [clinicaltrials:NCT00216372]Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer [clinicaltrials:NCT00262990]Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00288275]clinicaltrials:NCT00317772clinicaltrials:NCT00318370clinicaltrials:NCT00332696A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis [clinicaltrials:NCT00352755]clinicaltrials:NCT00382811ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma [clinicaltrials:NCT00407407]Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer [clinicaltrials:NCT00436657]Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas [clinicaltrials:NCT00443196]clinicaltrials:NCT00445549Quality of Life Questionnaire for Pediatric Patients Undergoing Peritoneal Perfusion [clinicaltrials:NCT00502177]A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00516841]Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire [clinicaltrials:NCT00517621]clinicaltrials:NCT00666991clinicaltrials:NCT00698451clinicaltrials:NCT01015118Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC [clinicaltrials:NCT01225757]clinicaltrials:NCT01314105clinicaltrials:NCT01384253Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer [clinicaltrials:NCT01462890]A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors [clinicaltrials:NCT01478685]clinicaltrials:NCT01681368An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA) [clinicaltrials:NCT01697488]clinicaltrials:NCT01846611HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry [clinicaltrials:NCT02082886]clinicaltrials:NCT02231086DNA Single Nucleotide Polymorphisms as Predictors of Toxicity [clinicaltrials:NCT02478476]
condition [clinicaltrials_vocabulary:condition]
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis [clinicaltrials:NCT00001332]Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis [clinicaltrials:NCT00001569]Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers [clinicaltrials:NCT00002538]Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00002600]Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00002717]Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer [clinicaltrials:NCT00002734]Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer [clinicaltrials:NCT00002894]Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00002895]SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) [clinicaltrials:NCT00002960]Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003064]clinicaltrials:NCT00003120clinicaltrials:NCT00003136Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum [clinicaltrials:NCT00003160]Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer [clinicaltrials:NCT00003322]Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00003345]Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003358]Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer [clinicaltrials:NCT00003378]Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00003380]Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer [clinicaltrials:NCT00003382]Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00003385]Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00003450]Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum [clinicaltrials:NCT00003523]Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003560]Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer [clinicaltrials:NCT00003624]Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy [clinicaltrials:NCT00003634]Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00003636]Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00003670]Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer [clinicaltrials:NCT00003880]clinicaltrials:NCT00003896Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003944]Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00003967]Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00003998]Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00004012]Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer [clinicaltrials:NCT00004037]Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00004060]Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00004064]Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu [clinicaltrials:NCT00004074]Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer [clinicaltrials:NCT00004081]Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors [clinicaltrials:NCT00004082]Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy [clinicaltrials:NCT00004115]
condition browse [clinicaltrials_vocabulary:condition-browse]
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis [clinicaltrials:NCT00001332]Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis [clinicaltrials:NCT00001569]Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers [clinicaltrials:NCT00002538]Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00002600]Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00002717]Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer [clinicaltrials:NCT00002734]Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer [clinicaltrials:NCT00002894]Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00002895]SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) [clinicaltrials:NCT00002960]Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003064]clinicaltrials:NCT00003120clinicaltrials:NCT00003136Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum [clinicaltrials:NCT00003160]Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer [clinicaltrials:NCT00003322]Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00003345]Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003358]Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer [clinicaltrials:NCT00003378]Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00003380]Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer [clinicaltrials:NCT00003382]Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00003385]Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00003450]Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum [clinicaltrials:NCT00003523]Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003560]Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer [clinicaltrials:NCT00003624]Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy [clinicaltrials:NCT00003634]Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00003636]Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer [clinicaltrials:NCT00003670]Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer [clinicaltrials:NCT00003880]clinicaltrials:NCT00003896Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00003944]Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00003967]Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00003998]Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [clinicaltrials:NCT00004012]Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer [clinicaltrials:NCT00004037]Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00004060]Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer [clinicaltrials:NCT00004064]Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu [clinicaltrials:NCT00004074]Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer [clinicaltrials:NCT00004081]Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors [clinicaltrials:NCT00004082]Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy [clinicaltrials:NCT00004115]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Peritoneal Neoplasms [clinicaltrials_resource:8436df17cb6a67e09076d0e4df2e0379]
Bio2RDF identifier
8436df17cb6a67e09076d0e4df2e0379
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8436df17cb6a67e09076d0e4df2e0379
identifier
clinicaltrials_resource:8436df17cb6a67e09076d0e4df2e0379
title
Peritoneal Neoplasms
@en
type
label
Peritoneal Neoplasms [clinicaltrials_resource:8436df17cb6a67e09076d0e4df2e0379]
@en
Peritoneal Neoplasms